Journal Article

Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma

Okabe, Ryuichi, Yamazaki, Keisuke, Sato, Yuichiro, Horii, Arata, Togashi, Takafumi, Yokoyama, Yusuke, Saijo, Kohei, Takano, Satoshi, Shodo, Ryusuke, Omata, Jo, Ohtaki, Kohei, Ohshima, Shusuke, Takahashi, Takeshi, Tanaka, Ryoko, Ueki, Yushi, Takahashi, Nao

2024

Overview

BackgroundThe optimal chemotherapy regimen in concurrent chemoradiotherapy (CCRT) for cisplatin-ineligible head and neck squamous cell carcinoma (HNSCC) has not been established. We aimed to evaluate the feasibility, efficacy, and safety of CCRT with weekly low-dose carboplatin for the treatment of advanced HNSCC in patients who are cisplatin-ineligible.MethodsThis prospective phase II study enrolled adult patients (age ≥ 20 years) with HNSCC receiving whole-neck irradiation including bilateral levels II–IV and who were aged (≥ 75-year-old patients with 40 mL/min estimated glomerular filtration rate [eGFR] or better) or had renal dysfunction (< 75-year-old patients with 30–60 mL/min eGFR). Carboplatin was administered weekly (area under the plasma concentration–time curve = 2.0) for up to seven cycles during concurrent radiotherapy (70 Gy/35 Fr). The primary endpoint was the completion rate of CCRT. Secondary endpoints included overall response rate and incidence of adverse events.ResultsAmong the 30 patients enrolled, 28 were men. The median age was 73.5 years. Seventeen patients were < 75 years whereas 13 were ≥ 75 years old. The completion rate of CCRT was 90%. The overall response rate was 90%. Grade 3 adverse events that occurred in 10% or more patients were oral/pharyngeal mucositis (47%), leukocytopenia (20%), and neutropenia (10%). Grade 4 adverse events occurred in one patient (elevation of alanine aminotransferase level). No treatment-related deaths occurred.ConclusionCCRT with weekly low-dose carboplatin is a promising treatment option, with favorable feasibility, efficacy, and acceptable toxicity, for patients who are cisplatin-ineligible with advanced HNSCC.Clinical Trial Registration NumberjRCTs031190028.

• Publisher: Springer Nature B.V
• Subject: Adverse events / Alanine transaminase / Carboplatin / Chemoradiotherapy / Chemotherapy / Cisplatin / Epidermal growth factor receptors / Glomerular filtration rate / Head & neck cancer / Head and neck carcinoma / Leukopenia / Mucositis / Neutropenia / Patients / Pharynx / Radiation therapy / Renal function / Response rates / Squamous cell carcinoma / Toxicity